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The immune system and metabolism are highly integrated and multilevel interactions 
between metabolic system and T  lymphocyte signaling and fate exist. Accumulating 
evidence indicates that the regulation of nutrient uptake and utilization in T cells is critically 
important for the control of their differentiation and manipulating metabolic pathways in 
these cells can shape their function and survival. This review will discuss some potential 
cell metabolism pathways involved in shaping T lymphocyte function and differentiation. 
It will also describe show subsets of T cells have specific metabolic requirements and 
signaling pathways that contribute to their respective function. Examples showing the 
apparent similarity between cancer cell metabolism and T  cells during activation are 
illustrated and finally some mechanisms being used by tumor microenvironment to 
orchestrate T-cell metabolic dysregulation and the subsequent emergence of immune 
suppression are discussed. We believe that targeting T-cell metabolism may provide 
an additional opportunity to manipulate T-cell function in the development of novel 
therapeutics.
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iNTRODUCTiON
It is well admitted that one of the mechanisms by which immune cells integrate the signals 
required for their proliferation, migration, differentiation, and effector functions is through the 
modulation of their metabolic activity (1). In this regard, T  cells metabolically reprogram and 
upregulate glucose and amino acid, to allow the synthesis of the new macromolecules required 
Abbreviations: AKT, serine/threonine-specific protein kinase; AMPK, AMP-activated protein kinase; ATP, adenosine triphos-
phate; CTLs, cytolytic T cells; CTLA-4, cytotoxic T-lymphocyte antigen; FAO, fatty acid oxidation; GLUT, glucose transporters; 
HIF, hypoxia-inducible factor; IFN-γ, interferon-γ; MHC, major-histocompatibility complex; mTOR, mammalian target of 
rapamycin; c-Myc, avian myelocytomatosis virus oncogene cellular homolog; OXPHOS, oxidative phosphorylation; PD-1, pro-
grammed death-1; PD-L1, programmed death ligand-1; PI3K, phosphatidylinositol-3 kinase; PPP, pentose phosphate pathway; 
PTEN, phosphatqase and tensin homolog; ROS, reactive oxygen species; TAA, tumor associated antigen; TCA, tricarboxylic 
acid; TCR, T-cell receptor; Teff, effector T cells; Th, helper T cells; TNF-α, tumor necrosis factor; Treg, regulatory T cells.
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for their proliferation and effector function (2, 3). Furthermore, 
beyond these key nutrients, iron uptake is also critical for T-cell 
function (4). Indeed, development and differentiation of antigen-
specific T  cells depend on iron uptake and internalization via 
type I transferrin receptor (5). Several previous studies suggested 
that iron deficiency impaired T-cell proliferation and cytokine 
production in activated T cells. Conversely, less is known about 
the effect of iron overload on T-cell function (6).
Nevertheless, how metabolism regulates immune T-cell 
differentiation, function, and plasticity remains very challeng-
ing and how immune cells function in terms of their intracel-
lular metabolism and how these metabolic pathways affect the 
phenotype and activation of immune cells is attracting a lot of 
attention at present. Tumor progression is characterized by a 
tangled network of relationships among different cell types that 
collectively exploit a metabolic reprogramming and mutually 
influence their functionality and, in particular, T-cell functions. 
Our recent knowledge of T-cell molecules involved in the regula-
tion of antitumor T-cell responses has led to the development of 
several monoclonal antibody-based therapies, against molecules 
like cytotoxic T-lymphocyte antigen (CTLA-4) or programmed 
death-1 (PD-1) (7). Although these treatments have shown 
unprecedented responses in some patients suffering from several 
cancers (8–10), the response rates are usually low and transient. 
This is likely due to multiple mechanisms suppressing antitumor 
immune functions within an unfavorable tumor milieu and 
metabolism. The metabolic activity of T  cells in the context of 
tumor microenvironment could be one of the key mechanisms.
It should be noted that the dynamic and reciprocal inter-
actions between tumor cells, metabolites, and a variety of 
cells including immune cells from the tumor microenviron-
ment orchestrate several events, which are critical for tumor 
evolution toward metastasis. In this context, many cellular 
and molecular elements of the tumor ecosystem are emerg-
ing as attractive targets for therapeutic approaches. Among 
these targets, hypoxia, which is a hallmark of solid tumors, 
is strongly associated with advanced disease stage and poor 
clinical outcome. This is, in part, due to inappropriate local 
immune reaction and resistance of hypoxic tumor cells to 
cytotoxic treatments. In fact, most human tumors develop a 
pathophysiological microenvironment during growth, char-
acterized by an irregular microvascular network and regions 
of chronically and transiently hypoxic cells. We and others 
provided evidence that hypoxia plays a crucial role in tumor 
promotion and immune escape by conferring tumor resistance 
(11) immunosuppression (12) and tumor heterogeneity (13), 
which contributes to the generation of diverse cancer invasion 
programs and enhanced stroma plasticity (11, 14). Therefore, 
it is of major interest to understand how immune cell intracel-
lular metabolism and some metabolic pathways influence the 
acquisition of their phenotype, the regulation of their activa-
tion and effector function. The metabolic activity of T  cells 
in the context of tumor microenvironment, its heterogeneity, 
and complexity is therefore an important consideration in 
immunotherapy. Clearly, if T  cells play the music during an 
adaptive immune response, the metabolic tumor microenviron-
ment calls the tune. Indeed, a better understanding of these 
metabolic related issues in relationship with T-cell activity may 
offer new therapeutic strategies in future to better control their 
plasticity and effector function and boost their efficacy and 
potential use in cancer immunotherapy approaches.
BASiC OveRview OF MeTABOLiSM  
iN T CeLLS
Metabolism is the process whereby cells can either break down 
molecules to generate energy in the form of adenosine triphos-
phate (ATP) or synthesize several macromolecules. Metabolism 
could be divided into two complex pathways: the catabolic 
processes, critical for cellular proliferation and functions and the 
anabolic process, important for cellular growth.
Consistent studies focused on the molecular mechanisms that 
dictate metabolic reprogramming in the immune cells (15). It is 
now widely appreciated that T-cell metabolic remodeling plays 
a key role to shape immune response, in particular, antitumor 
immunity. Profound metabolic changes occur under tight regula-
tion allowing T cells to maintain energy balance between anabolic 
and catabolic metabolism, which support adequate immune 
responses (16, 17).
During quiescence, T cells require energy-oriented oxidative 
metabolism and relatively small amounts of glucose, amino 
acids and fatty acids to maintain basic energetic, primarily 
anabolic and minimal replacement biosynthesis demands. 
Encounter with cognate antigen activation, T-cell stimulation 
by T-cell receptor (TCR) ligation and binding with costimula-
tory molecules induce metabolic remodeling (18, 19). In fact, 
metabolism shifts to glycolysis to support rapid growth and 
to biosynthesis for differentiation into effector T cells (Teff) (1, 
20, 21) (Figure  1A). Albeit, aerobic glycolysis is less efficient 
than oxidative phosphorylation (OXPHOS) at yielding ATP, 
it generates metabolic intermediates which are important for 
cell growth and proliferation as well as for cytotoxicity and 
cytokine production. Nevertheless, glycolytic pathway generates 
macromolecule precursors required in the pentose phosphate 
pathway (PPP) for cell growth and NAD phosphate (NADPH) 
production important for anabolic pathways and maintaining 
redox balance (22).
After pathogen clearance, most T cells go through apoptosis 
while few of them remain as long-lived memory cells responsible 
for enhanced immunity against upcoming pathogens or tumors 
re-exposure (23).
DiSTiNCT MeTABOLiC PROGRAMS  
FOR T CeLLS DiFFeReNTiATiON 
AND FUNCTiON
T lymphocytes (T cells) that undergo an immune response con-
stitute an ideal system to study the rapid shift from quiescent to 
active state that belongs to growth, proliferation, and differentia-
tion into largely heterogeneous T-cell subsets. Emerging concepts 
in immunology suggest that lymphocyte activation is intricately 
linked to metabolic reprogramming (24–26). In fact, metabolism 
fundamentally underpins T-cell function and lymphocytes 
AB
FiGURe 1 | Metabolic reprogramming drives: (A) T-cell fate and function and (B) antitumor-immune response. (A) Upon activation through T-cell receptor 
(TCR) and costimulatory signals, T cells engage in growth, and differentiation into different cytotoxic, regulatory T cells (Treg), helper T (Th), and memory T (Tm) 
subsets cells. Metabolic reprogramming has been shown to intimately support T-cell activation and differentiation. While naïve T cells rely on oxidative 
phosphorylation (OXPHOS) to maintain energy demand; activated T cells engage increased aerobic glycolysis and glutaminolysis consuming massive amount of 
glucose and glutamine, enabling to generate effector cytokines, including interferon-γ (IFN-γ) and IL-2. In contrast to cytotoxic and effector Th cells, the metabolic 
profile of Treg and Tm cells rely on OXPHOS and fatty acid oxidation (FAO) to support their survival and differentiation. The central energy-monitoring system 
underlying this metabolic remodeling is the phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway that boosts 
glycolytic activity in T cells via activation of transcription factors hypoxia-inducible factor-1α (HIF-1α) and Myc pathways. (B) Tumor-specific T cells are often rendered 
dysfunctional due to an immunosuppressive microenvironment. Infiltrating T cells are reprogrammed by the tumor favoring its survival and immune escape. Cancer 
cells induce several metabolic changes in the microenvironment. Tumor-mediated decreased extracellular nutrients levels cause impaired glycolysis capacity and 
IFN-γ production in T cells. Cancer cells also generate a hypoxic microenvironment. Hypoxia stabilizes HIF-1α and enhance glycolysis in tumor cells, a phenomenon 
recognized as “the Warburg effect.” HIF-1α also enhances constitutive expression of programmed death ligand-1 (PD-L1) leading to activation of Akt/mTOR 
pathway. Activating immune checkpoints and PD-L1 signaling through binding to its receptor programmed death-1 (PD-1) leads to dampening of the Akt-mTOR 
pathway and reduced T-cell glycolysis. Collectively, tumor environment affects metabolic fitness of infiltrating immune cells and drives impairment of antitumor 
effector function and increased tumor progression.
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metabolism is dynamically regulated depending on their sepa-
rate phases of development: (1) naïve or resting, (2) effector or 
activated, and (3) memory T (Tm) cells (27).
Naïve T  cells are activated to rapidly respond to foreign 
pathogens or inflammation through a tight interaction with 
the TCR and major-histocompatibility complex. Further, 
T  cells enter the effector phase of rapid growth, proliferation, 
and differentiation. Teff could be divided into cytolytic T cells, 
secreting granzyme B, perforin, interferon-γ (IFN-γ), into 
helper T  cells (Th) including the type-1 (Th1), type-2 (Th2), 
and type-17 (Th17) producing characteristic cytokines or into 
regulatory T cells (Treg) (28, 29). Teff play a pivotal role to medi-
ate antitumor immunity. Hence, Treg obstruct Teff activity and 
suppress immunity, showing a poor prognosis in many cancers 
(30). After expansion phase and antigen clearance, most clonally 
differentiated T cells undergo apoptosis, while a small fraction 
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become quiescent Tm cells, responsible for enhanced immunity 
after re-exposure to the pathogen (31, 32). The differences in 
functional and phenotypic characteristics of quiescent T  cells 
and activated T  cells are supported by differential metabolic 
requirements (17). Each subset of T-cell demonstrates unique 
metabolic demands and signaling pathways that contribute to 
its fate and function (25).
Quiescent T cells and activated T-cell fate are characterized 
by different metabolic pathways (33–35). Globally, activated 
T cells adopt an anabolic metabolism supporting rapid prolif-
eration whereas quiescent T cells engage catabolic metabolism 
(36). Teff subtypes switch their metabolic program to robust 
aerobic glycolysis, but increased glycolytic rates occurred much 
higher in Th1, Th2, and Th17  cells than in Treg cells (24). Treg 
cells sustain enhanced fatty acid oxidation (FAO) metabolism 
as a major source of energy to maintain their survival (37–39). 
Upon antigen encounter, upregulation of aerobic glycolysis in 
extensive proliferating T  cells is accompanied with glutami-
nolysis, PPP, not only to support ATP generation, but also to 
enhance biosynthesis of crucial intermediates and precursors 
necessary for subsequent macromolecules that are incorporated 
into cellular biomass (40, 41) (Figure  1A). Th17  cells rely, in 
particular, on increased glycolysis. Hence, inhibiting glycolysis 
during Th17  cell differentiation re-enforce Treg generation 
(42). Nevertheless, consistent data suggest that mitochondrial 
reactive oxygen species (ROS) produced during OXPHOS is 
also crucial to activate T-cell and to enhance antigen-specific 
proliferation. However, excessive ROS levels are toxic for T cells 
and leads to apoptosis (43). CD4 +  regulatory T lineage cells 
exhibit a mixed metabolic program involving mainly FAO 
and OXPHOS and low level of glycolysis (44). Treg favor FA 
catabolism via b-oxidation and prioritize oxidative ATP to meet 
their energetic demands, an important metabolic phenotype for 
the differentiation of Treg (38).
After the clearance of pathogens, the remaining antigen-
specific T cells (Tm cells) as a quiescent T-cell population share 
common metabolic requirements with other nonproliferating 
cells. Tm cells maintain catabolic profile with lower nutrient uptake 
and biomass synthesis and predominantly engage mitochondrial 
OXPHOS and FAO metabolism for long-term persistence, ATP 
production and the capacity to vigorously respond to antigen 
stimulation (45). Several studies revealed that maintaining mito-
chondrial mass is critical for Tm cells development since it offers 
the opportunity to use a wide range of substrates responsible 
for energy generation, like fatty acids (46, 47). FAO constitute 
a preferred fuel source for Tm cells as this lipid oxidation gener-
ates intermediate of tricarboxylic acid (TCA) cycle related to 
OXPHOS metabolism. However, their detailed metabolic profiles 
remain to be explored (25).
Metabolic regulation of T-cell fate and function involves a 
network of molecular regulators. The main induced signaling 
pathways underlying the activation through the TCR with 
CD28 costimulation, is the phosphoinositide 3-kinase/protein 
kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) 
(48–50). Increasing evidences suggest that the mammalian 
target of rapamycin (mTOR) is a central regulator of cell 
metabolism. Interestingly, T-cell differentiation to effectors 
or Tm cells is governed in part by asymmetric partitioning 
of fate determining proteins (51, 52). Recent study dem-
onstrates that asymmetric division of T  cells generates two 
sets of daughter cells with differential mTORC1 activity (53). 
The first set exhibits increased activity mTORC1, as well as 
high levels of glycolysis and effector molecules expression. 
Besides, the second T-cell set shows decrease in mTORC1 
activity associated with enhanced rates of lipid metabolism 
and antiapoptotic molecules. Behind, the latter daughter cells 
display enhanced long-term survival and differentiate to Tm 
cells (53). This pathway plays key transcriptional and post-
transcriptional roles to promote anabolic gene expression and 
intracellular trafficking of nutrient transporters (54). mTOR 
is the downstream target of the PI3K–AKT signaling and a 
central player governing metabolic reprogramming and fate of 
T-cell (55–57). Two major transcription factors are upregulated 
by mTOR: avian myelocytomatosis virus oncogene cellular 
homolog (c-Myc) and hypoxia-inducible factor-1α (HIF-1α) 
(58, 59) (Figure 1A). It has been shown that c-Myc is crucial 
to activate glucose transporters (GLUT) and key enzymes 
for enhancing glucose influx and glycolysis that accompany 
early stage of T-cell growth, proliferation, and the transition 
from a naïve T-cell to a Teff cell (60). Furthermore, c-Myc is 
responsible for enhanced glutaminolysis by inducing glutamine 
transporters and glutaminase1 expression to sustain cell growth 
and proliferation (60, 61).
Hypoxia-inducible factor-1α is another master transcription 
factor monitoring glycolytic enzymes expression (62, 63). HIF-
1α acts also to downregulate mitochondrial oxygen consump-
tion and inhibit TCA cycle. At later times of differentiation, the 
role of HIF-1α appears more complex to mediate T-cell fate and 
function (64). HIF-1α is reported to play a more selective role in 
inflammatory Th17 CD4 T-cell subsets (42) and cytolytic CD8 
T (58). In addition, HIF-1α appears to influence the balance 
of Th17:Treg cells (65). Indeed, it directly promotes glycolysis 
in differentiating Th17  cells and reciprocally increases Th17 
differentiation and decreases Treg differentiation (66). However, 
in vitro and in vivo studies demonstrate that a lack of HIF-1α 
strongly impair Th17 cell development and drives Treg cell dif-
ferentiation and FAO. Treg cells unlike other Teff cells mainly 
display increased FAO metabolism and enhance AMP-activated 
protein kinase (AMPK) activation (67). The utilization of lipid 
oxidation by Treg cells might play a central role in their survival 
advantage over Teff cells and in the maintenance of a stable pool 
of pro-tumor (68, 69).
Finally, the mechanisms regulating the transition of T  cells 
from effector to memory states remain to be elucidated. Recent 
studies demonstrated that mitochondrial FAO in Tm cells require 
stimulation of tumor necrosis factor receptor-associated factor 6 
pathway (70). Further, memory CD8+ T-cell development is also 
supported by activating the energy sensor AMPK pathway (71, 
72). FAO has clinical implications for memory CD8+ T as well 
as for Treg cells (73). In fact, administration of metformin or the 
mTOR inhibitor rapamycin, reduce mTOR activity and induce 
AMPK phophorylation that in turn perform lipid oxidation and 
enhance the formation of Tm cells after infection and increase Treg 
responses in asthma model (74, 75).
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FUeLiNG T-CeLL PROLiFeRATiON
Increasing data suggest that regulation of metabolic fuels uptake 
is a critical component of T-cell activation to accomplish their 
functional requirements. Yet, limiting conditions could suppress 
the suitable access to nutrients, causing a barrier to T-cell func-
tion. To maintain a proper response, T-cell activation requires 
the upregulation of both glucose and amino acid transporters 
(1, 76). Several metabolic pathways that are imminent for 
lymphocyte proliferation are supported by the availability of 
these fuels (24).
Glucose
Glucose is the most used nutrient predominantly existing in the 
surrounding environment, and glucose metabolism, in particular, 
is essential for T cells for normal survival and function. Glucose 
is a critical substrate for energy production, and its deprivation 
prevents T-cell function despite the presence of other alternative 
carbon source (77, 78). When Teff are activated, glucose uptake 
raises to maintain aerobic glycolysis and subsequently to support 
growth and proliferation, whereas glucose use via OXPHOS is 
decreased (79). Further, the expression and trafficking patterns of 
GLUT are upregulated allowing T cells to enrich their intracellular 
glucose. The GLUT consists of 14 different members (GLUT1–14) 
relying on diverse substrate specificities (80). GLUT2 and GLUT3 
are expressed in resting human peripheral blood T cells, while 
GLUT1 is expressed at a low level in naïve T cells, but rapidly 
induced upon T-cell activation. Consequently, overexpression of 
GLUT1 after TCR activation leads to increased glucose uptake and 
enhanced expression and activity of glycolytic enzymes. During 
glycolysis, glucose is not fully oxidized in the mitochondria but 
rather broken down into pyruvate that is converted into lactate 
even though in presence of sufficient oxygen (81). Glucose could 
be also derived toglucose-6phosphate and further directed into 
the PPP, providing precursors for the synthesis of nucleotides and 
aromatic amino acids (77).
It has also been reported that T-cell cytokine production is 
also relying on glucose. In fact, data showed enhanced T-cell 
cytokine production such as IL-2 and IFN-γ in transgenic model 
expressing GLUT1 specifically in T cells (78). In contrast, glucose 
deprivation has been shown to strongly inhibit cytokine produc-
tion and to decrease cytolytic activity of CD8+ T cells, marked 
by reduced granzyme and perforin production. Thus, failure to 
properly upregulate glucose metabolism during T-cell activation 
can lead to impaired proliferation. As a consequence, T cells can 
enter to anergy if they survive this metabolic stress, or they die by 
apoptosis. Collectively, glucose is fundamental to support prolif-
eration and effector functions that accompany clonal expansion 
of Teff. Besides, Treg cells do not depend on high rates of glucose 
as they express low levels of GLUT1 and rely on lipid oxidation 
for energy (39).
Glutamine
Glutamine is a nonessential amino acid and the most abundant 
nutrient in the blood. Glutamine constitutes also a critical 
substrate for T  cells activation and growth process. Following 
T-cell activation through efficient TCR signaling, the uptake and 
biosynthesis of amino acids or amino acid transporter expression 
are dramatically increased (82, 83).
Glutamine catabolism is dramatically induced in active T cells 
providing intermediate molecules necessary for different pathways 
of biosynthesis and substrates for mitochondria (84, 85). During 
glutaminolysis, glutamine carbon backbone can be converted to 
α-ketoglutarate to maintain homeostasis of the TCA, or to lactate 
that generates NAD and NADPH (86). During T-cell activation 
glutamine can be used, providing pyruvates to overcome intense 
aerobic glycolysis levels (87). Further, activated T cells selectively 
increase glutamine uptake. This increase has been suggested to 
be concomitant with induced expression of glutamine transport-
ers, recognized as members of the sodium-dependent neutral 
amino acid transporter (SNAT) family. In fact, the previous study 
demonstrates rapidly enhanced mRNA expression of SNAT1 and 
SNAT2 isoforms after in vivo stimulation of T cells (82). However, 
lack of glutamine can result in profound inhibition of cell growth, 
proliferation, and cytokine production (88). Since T-cell activa-
tion is strongly impacted by glutamine, thus different aspects of 
glutamine metabolism could serve as novel targets for immune 
modulation.
Tryptophan and Arginine
In addition to glutamine, other limiting amino acids such as 
tryptophan and arginine have been suggested to be crucial for 
T-cell activation and function. This concept has gained interest 
especially in cancer context, where tumor-induced extracellular 
depletion of these amino acids alters T-cell activity and causes 
their anergy. Tryptophan is an essential amino acid required for 
the production of several important molecules and its catabolism 
through the kynurenine pathway generate metabolites such 
as kynurenine, kynurenic acid, 3-hydroxy-kynurenine, and 
3-hydroxy-anthranilic acid (89). Numerous studies showed that 
tryptophan plays a key role in T-cell survival and activation 
whereas its metabolites eliminate T-cell function and are able to 
induce T-cell apoptosis (90). Teff are affected by the decrease in 
tryptophan concentrations and high rates of toxic tryptophan-
metabolites induced by mature antigen-presenting cells 
expressing enzymes that catabolize tryptophan (91). Tryptophan 
degradation is one of a resistance mechanisms adopted by 
tumors to avoid immune suppression (92, 93). Three enzymes 
were identified to control tryptophan degradation through the 
kynurenine pathway: tryptophan-2,3-dioxygenase, indoleamine 
2,3-dioxygenase 1, and indoleamine 2,3-dioxygenase. Hence, 
T-cell cycle progression is prevented and Teff cells shift to anergy 
and apoptosis. In hostile tumor microenvironment context, 
such inhibition is resulting in suppression of antitumor immune 
responses (94).
In addition to tryptophan, arginine has gained much attention 
as an important amino acid in T-cell function. Arginine is a ver-
satile amino acid engaged in protein synthesis and in generating 
many metabolites precursors including, polyamines, and nitric 
oxide involved in immunometabolism (95). Indeed, deficiency 
in extracellular arginine or in enzymes responsible of de novo 
synthesizing arginine [argininosuccinate 1 (ASS1)], has been 
found to critical during activation (96). Low levels of arginine 
impair T-cell proliferation, aerobic glycolysis and reduce cytokine 
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production and expression of activation markers such as CD25 
and CD28 (97, 98). Further, deletion of ASS1 blunt in vitro Th1 
and Th17 cell polarization, even in the presence of extracellular 
arginine (99). Interestingly, recent study showed that increased 
arginine levels display improved survival capacity of T memory 
cells and antitumor activity (95). Taken together and according 
to the beneficial effect of arginine and tryptophan on T-cell meta-
bolic adaptation and antitumor activity, both amino acids would 
be exploited as an attractive target for therapeutic intervention in 
antitumor response (96).
wARBURG eFFeCT OR HOw CANCeR 
CeLL RewiRe MeTABOLiC PROGRAM
It is well established that cancer cells must reprogram cellular 
pathways to enable their growth and proliferation. Tumor cells 
reprogram their metabolic pathways and rely upon increased 
glucose uptake and high rate lactate production, principally 
through aerobic glycolysis (100), regardless of the level of oxy-
gen (101). Metabolic switch of cancer cell supports biosynthesis 
of essential macromolecules (nucleic acids, lipids, and amino 
acids), through interconnected pathways. This metabolic 
program was recognized since 1920s by Otto Warburg as the 
“Warburg effect” (102, 103), a strategic metabolic adaptation 
enhancing rapid tumor growth, proliferation, and to dampen 
antitumor immunity, thus representing one additional hallmark 
of cancers. Since 1923, Otto Warburg has reported that cancer 
cells acquire irreversible switch of their energy-producing 
machinery from mitochondrial OXPHOS respiration, to 
aerobic glycolysis (104). Glycolysis is a predominant energy 
source for cancer cells, occurring either under aerobic or 
hypoxic conditions to produce large amounts of lactate, and 
much less efficient than OXPHOS for producing ATP (105, 106) 
(Figure 1B). This reprogramming of cancer cell metabolism has 
been acknowledged recently as a hallmark of cancer with many 
faces (107, 108). By analogy to immune cells, similar metabolic 
features with T cells during activation are observed. But, despite 
an apparent similarity, there is deep down a wide difference 
between glycolysis in activated T  cells and cancer cells. Such 
metabolic transitions in T  cells are part of a physiological 
adaptation process. However, intrinsic genetic mutations and 
external responses to the tumor microenvironment monitor 
the metabolic phenotype of tumor cells (109, 110). Cellular 
dysregulation of oncogenic signaling pathways are the result of 
the loss of tumor suppressors (such as p53) or the activation of 
oncoproteins (such as PI3K) (111). As a consequence, cancer 
cells thereby gain selective growth and survival (112).
Cancer cells use the Warburg effect as strategic metabolic 
adaptation to satisfy their urgent requirements for growth and 
proliferation under tumor microenvironmental limitations for 
oxygen and nutrients (113, 114). Under hypoxic conditions, 
cancer cells accelerate metabolism that lead to increased NADPH 
rate to cope with higher ROS levels (115, 116). Thus, the Warburg 
effect also supports tightly controlled redox balance for cancer 
cells, considered as important survival mechanism (117).
Glucose is considered as prominent player in the alterations 
of metabolism and energetic of cancer cells (118). Increased 
glucose uptake lead to upregulated glycolysis and thus more 
pyruvate is produced even in normoxia conditions. Under limited 
oxygen availability (hypoxia), more pyruvate avoids TCA cycle 
and generates excess of lactate secreted thereby in the tumor 
microenvironment (118, 119). In addition to its central role as a 
carbohydrate nutrient for ATP synthesis, new evidence revealed 
that high glucose uptake is also important for biomass synthesis 
needed for rapidly proliferating cancer cells. Upregulation of 
glycolysis increased several metabolic intermediates that may 
be shunted to interconnected pathways, as PPP (120, 121). The 
resulting glycolytic intermediates such fructose-6-phosphate, 
glyceraldehyde-3-phosphate, and 3-phosphoglycerate are critical 
for de novo synthesis of ribonucleotides, amino acids, and phos-
pholipids, respectively (122).
Glutamine is the most abundant free amino acid and essential 
source of carbohydrate for proliferating cells. Cancer cells display 
increased glutamine demand and consumption. Interestingly, the 
glutamine dependence extends beyond protein synthesis to other 
important requirements (123). Rapidly proliferating, cancer cells 
use glutamine to fuel biosynthesis of nucleotides, to replenish 
TCA cycle intermediates through a process called anaplerosis, or 
to be taken from the mitochondria and then modified into lactate 
(glutaminolysis) (124, 125). Glutamine metabolism occurs in 
cancer cells, in general, with concomitant production of NADPH 
that not only maintains cellular redox but also reduces agent 
in varied biosynthetic pathways–underlying de novo fatty acid 
synthesis (126).
The molecular drivers that lead to the shift of cancer cell from 
oxidative to glycolytic metabolism are distinct and tend to happen 
simultaneously. Cancer metabolism adaptation to the anabolic 
program has been suggested to be under direct management by 
various transcription factors, such as Myc and hypoxia-inducible 
factor 1 (HIF-1) (127, 128).
Myc is a transcription factor upregulated in tumors and 
considered as master regulator of normoxic cancer cell repro-
gramming (129). Indeed, Myc contributes to cancer cells switch 
to aerobic metabolism by facilitating cellular glucose uptake 
and activating the expression of numerous genes essential for 
glycolysis. Furthermore, Myc plays important role to promote 
macromolecules synthesis and mitochondrial biogenesis, critical 
for fast developing cancer cells (130, 131).
Upon rapid proliferation, hypoxia becomes a key mediator 
of the Warburg effect and a common feature of human tumors. 
Extensive studies have provided evidence that cancer cells utilize 
hypoxia as physiological adaptation pathway that promotes 
metabolic changes in fast growing tumors (132). Indeed, under 
hypoxic tumor microenvironment, the uptake of glucose and the 
glycolytic flux are increased. This metabolic adaptation is mainly 
orchestrated through the upregulation of the transcription fac-
tor, HIF-1α. HIF-1α is induced by low oxygen conditions and 
recognized as independent marker of poor prognosis (133, 134). 
The activated tumor glycolytic flux involving HIF-1α implies 
upregulation and increased activity of several glycolytic protein 
including key glycolytic enzymes (HK2, PFK-L, PKM2, and 
LDH-A) and GLUT (GLUT1 and GLUT3) (135, 136). In contrast 
to Myc, HIF-1 strongly inhibits mitochondrial respiration and 
biogenesis (111).
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Furthermore, PI3K/Akt/mTOR is one of the most frequently 
altered signaling pathway known to play an important role in 
glycolysis, cancer metabolism and cancer cell proliferation (137, 
138) (Figure 1B). It is well known that this pathway is activated 
under the loss of function of the tumor suppressor gene phos-
phatqase and tensin homolog. The best studied driver of tumor 
glycolytic program in such pathway. The latter has been reported 
to induce GLUT expression and to stimulate phosphorylation 
of key glycolytic enzymes (139). In addition, AKT1 strongly 
activates mTOR signaling pathway. Hence, mTOR is constitu-
tively activated during tumorigenesis (140) and constitutes a 
key metabolic issue, coupling cell growth to protein, and lipid 
biosynthesis (141).
TUMOR MiCROeNviRONMeNT 
ABROGATeS T-CeLL MeTABOLiC 
AND iMMUNe CHeCKPOiNTS
Immuno-metabolism plays a key role of adaptive immunity and 
is particularly central to effective antitumor T-cell responses. 
T  cells, following the metabolic strategies of growing tumors, 
have to start their effector programs. However, most of human 
tumors proliferate in spite of the presence of tumor associated 
antigen-specific T  cells. In fact, tumor microenvironment may 
impose several limitations to dampen T-cell immunity (142) and 
deplete crucial nutrient availability and handling, such as glucose 
or amino acids (143). It can also stimulate conserved negative 
feedback mechanisms, such as through PD-1 (144). Besides, 
tumor cells must evade the checkpoint controls under such stress-
ful metabolic conditions.
Tumor microenvironment is a forbidding environment that 
can pose significant metabolic challenges for infiltrating T cells 
to impair the effectiveness T-cell response. It is likely that T cells 
undergo immune suppressive networks that impair their specific 
functions and thereby enable tumor escape (145, 146). Many dif-
ferent molecular and cellular mechanisms have been proposed to 
contribute to the failure of T cells in tumor eradication. Recent 
studies have started to reveal that the feature and function of Teff in 
tumors are severely influenced by the tumor microenvironment 
context (147). Indeed, tumor microenvironment components 
form a very complex immunosuppressive network in cancer 
(148), lead to metabolic and immune checkpoints abrogation, 
which limits T-cell activation and induces T-cell dysfunction 
(149, 150). However, the exact mechanisms remain insufficiently 
understood.
Evidence is beginning to emerge suggesting that alterations 
of the T-cell metabolic pathways are critical to impair antitumor 
immunity, supporting immune escape (151). Cancer cells are 
recognized to be the most important players in tumor micro-
environment mediating immune suppression. In fact, metabolic 
interplay and nutrient (glucose and glutamine) competition 
between cancer cells and T  cells exist. Such competition is 
recognized as a key driver of cancer progression (152, 153). 
Due to high demand for energy and increased glucose addic-
tion and glycolysis rate, fast growing cancer cells consumes 
most nutrients and specifically increases rate of glucose intake, 
from the surrounding environment (154). As a consequence, 
tumor-imposed metabolic restrictions can mediate T-cell hypo-
responsiveness during cancer. T cells dramatically reduced gly-
colysis and become unable to produce cytokines and to develop 
into tumor-specific Teff cells, leading to a state of anergy (155) 
(Figure 1B). Thus, Treg cells differentiation is favored to inhibit 
antitumor immune response, instead of expansion of tumor-
specific T cells (156, 157). As a contrast to Teff that suffer from a 
hostile tumor microenvironment, Treg cells, feel comfortable with 
a similar environment (158). This is possibly the result of to the 
flow in growth factors (such as transforming growth factor-β) 
and chemokines (such as CCL22) promoting Treg differentiation 
and recruitment (156, 159). One molecular explanation is that 
alteration of functional fate of T cells due to nutrient limitation 
could occur through modulation of metabolically sensitive sign-
aling pathways. Under tumoral context, the balance between Teff 
and Treg may be directly disturbed when AMPK signaling path-
way inhibits mTORC (56, 160). Opposing to mTORC, AMPK is 
activated in conditions where nutrients are limiting and promote 
oxidative metabolism (161) (Figure 1B). AMPK can be highly 
phosphorylated and activated in Treg. Consequently, Teff function 
is impaired while Treg cells are promoted. Furthermore, Treg cells 
have also been reported to be induced under hypoxic tumor 
microenvironment, through over activated HIF-1α (12, 162). 
The presence of Treg in solid tumors essentially correlates with 
poor prognosis (27).
Immunosuppressive tumor microenvironment is also char-
acterized by elevated rates of ROS (115). Besides cancer cells, 
tumor-infiltrating leukocytes, including myeloid-derived sup-
pressor cells, tumor-associated macrophages, and Treg, also gener-
ate excessive ROS (163). It has been demonstrated that high level 
of ROS in the tumor microenvironment downregulates T-cell 
activity and enhanced T-cell apoptosis, inhibiting subsequently 
antitumor immune response (164). However, although high 
levels of ROS impair T-cell metabolism and function, ROS at a 
low or moderate-concentration is indispensable for T-cell activa-
tion and effector function (165). Considering the paradoxal effect 
of ROS on T-cell function a tight balance between production 
and consumption of ROS should be accomplished to potentiate 
antitumor activity compromising Teff function.
Under immunosuppressive tumor microenvironment T cells 
acquire an “exhausted” phenotype highlighted by upregulation 
of inhibitory receptors. Interestingly, to eradicate effectiveness 
of antitumor immune response, tumor hostile environment act 
not only to impair metabolic checkpoints of Teff cells encounter-
ing tumor antigens, but also to abrogate immune checkpoints. 
Indeed, several negative feedback mechanisms are stimulated, 
such as PD-1 and CTLA4 pathways (166, 167), which can both 
promote T cells exhaustion (Figure 1B). Hence, further research 
is needed to identify new target to reverse exhaustion in addition 
to PD-1 and CTLA4.
Programmed death-1 is the major inhibitory receptor in 
T cells regulating T-cell exhaustion. Interaction of PD-1 with its 
ligand programmed death ligand-1 (PD-L1), allows the tumor to 
evade immune system by inhibiting T-cell function (168, 169). 
Recently, it has been reported that upon ligation, T cells receiving 
PD-1 signals can lower the capacity of T cells to express GLUT1, 
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uptake glucose, and become unable to engage in glycolysis, 
glutaminolysis, or metabolism of branched-chain amino acids 
(144). Interestingly, PD-1 displayed an increased rate of FAO of 
endogenous lipids, and lipolysis is indicated by elevation of the 
lipase ATGL and by release of fatty acids (144). PD-1 signaling 
is associated with reduced cMyc expression and inhibition of 
activity of the PI3K/Akt/mTOR pathway, necessary for effector 
function (50, 170, 171). Besides, PD-L1 directly regulates tumor 
metabolism. Surface expressed PD-L1 is important for Akt/mTOR 
signaling to promote mTOR activity and glycolytic metabolism in 
tumor cells (172, 173).
Nonetheless, CTLA4 signaling also plays a key role in tumor 
immune escape since it inhibits CD28-mediated costimulation 
of Teff and favors Treg expansion (174, 175). Subsequently, CTLA4 
may broadly impair Teff cell activation against antigenic stimula-
tion in part by reducing the capability of Akt to enhance GLUT1 
expression, glucose uptake, and aerobic glycolysis, but without 
enhanced FAO as for PD-1 pathway (151).
iMMUNe CHeCKPOiNTS TARGeTiNG FOR 
eNHANCiNG T-CeLL FUNCTiON: 
ReLATiONSHiP wiTH MeTABOLiSM
Metabolic reprogramming plays a pivotal role for appropriate 
T-cell activation that supports antitumor immunity. However, 
T-cell function is compromised by the immunosuppressive 
tumor microenvironment. Nevertheless, multiple mechanisms 
that instruct the development of immune suppression may 
exist to prevent effective antitumor response, but remain 
largely unclear. Metabolic and functional pathways in T  cells 
may uncover new targets and challenges for cancer therapy 
(176). Therefore, manipulating metabolism may be a way to 
beneficially enhance or temper antitumor immunity. Current 
attractive therapeutic approaches which specially target T-cell 
metabolism are meant to use immunotherapy directed against 
several negative immunologic regulators CTLA-4 and PD-1/
PD-L1 pathway (177–179).
In recent studies, it has been reported that mice exhibiting or 
transplanted with tumors were treated with checkpoint blockade 
therapy, such blockade increased the glucose concentrations in 
the extracellular tumor milieu and TILs from these mice had 
increased glucose uptake, glycolytic rates, activated mTORC1 
pathway, and IFN-γ production (152). The same effects were 
reported after PD-L1 blockade or RNA interference directed 
against PD-L1 in cultured tumor cells (152). More importantly, 
T cells in allogeneic PD-L1−/− bone marrow transplant recipients 
had elevated levels of GLUT1 and lactate production, suggesting 
a normal in vivo role for PD-1 signaling to restrain T-cell glucose 
metabolism (180).
Although there is a promising efficacy of immunotherapy, 
the clinical benefit has been restricted by tumor-derived immu-
nosuppression and its related coinhibitory signals. Indeed, to 
escape antitumor immune response, tumors develop different 
strategies including secretion of immunosuppressive cytokines 
and chemokines (TGF-β, IL-10, VEGF, CCL2, and CCL12) (181) 
or immunosuppressive converting tryptophan and arginine 
enzymes [indoleamine-2,3-dioxygenase (IDO) and arginase, 
respectively] (98, 182, 183). In light of this, it would be reason-
able to combine immunotherapy with an immunosuppression-
blocking protocol. In particular, IDO is an attractive area for 
exploitation to potentiate immunotherapy, since it is highly 
expressed in the microenvironments of various tumors (184). 
Recently, preclinical studies demonstrate the efficiency of two 
IDO inhibitors to attenuate tumor growth (185, 186). Currently, 
IDO inhibitors entered clinical trials (187). Interestingly, in vivo 
study has been conducted on mouse melanoma model where 
synergistic immunotherapy strategy that locally targets PD-1 
and IDO for the treatment of melanoma has been developed. The 
preliminary results are quite encouraging and showed enhanced 
Teff cells and antitumor efficacy (188).
Therefore, the use of metabolism-targeting drugs working 
with checkpoint inhibitors might not only change the activation 
and differentiation program of tumor-specific T  cells but also 
prohibit the generation of exhausted T cells. Currently, there is a 
lack of data taking into consideration the metabolic consequences 
occurring in T cells and/or tumor cells by targeting these immune 
checkpoint pathways. Nevertheless, combined immunotherapeu-
tic strategies would be exciting and show promise to improve the 
anticancer efficacy of immunotherapy in the future.
CONCLUDiNG ReMARKS
It is widely admitted that tumors are not autonomous masses of 
cells but function as organs composed of many interdependent 
cells supporting malignant cell survival, growth and progres-
sion. To ensure tumor growth and immune evasion, the tumor 
stromal components undergo numerous metabolic adaptations, 
reprogramming the mode of energy generation. T cells play key 
role in the orchestration of the immune response and T-cell 
metabolic adaptation acts as crucial checkpoint hijacked by 
tumors to dampen antitumor immunity as T cells are rendered 
dysfunctional, unable to carry out their effector functions. 
Accumulating evidence indicate that the diverse functions of 
the immune system require several bioenergetic processes and 
that T-cell metabolic reprograming relies upon the activation of 
distinct transcriptional and signaling pathways. In the context of 
tumor microenvironment, tumors impose several limitations to 
dampen T-cell immunity as T cells, experiencing the metabolic 
framework of growing tumors, fail to activate distinct pathways to 
accomplish their functional requirements. Tumor microenviron-
mental hypoxia is in this regard a relevant example demonstrating 
how the tumor microenvironment of a tumor can paralyze and 
neutralize T-cell functions. In fact, O2 is a master regulator of 
the CD8+ T-cell response and T lymphocytes face pathologically 
low O2 tensions within the tumor bed at which they will have 
to function. It has become clear that tumor-imposed metabolic 
restrictions may result in an impairment of T-cell function and 
that either some programmed changes or pathologic manifesta-
tions can inhibit the required energy essential for their several 
functions. Accordingly, attempts are made to identify approaches 
aiming at manipulating the reprogramming of T-cell metabolic 
pathways for therapeutic purposes, in particular, antitumor 
immunity.
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